Postdoctoral fellow in immuno-oncology (F/M)

Laboratory

Institut Curie is one of the largest European institutions for cancer and biomedical research with strong interdisciplinary traditions. It is located in the center of Paris in France, in a both cultural and scientific rich environment. The site has active seminar program and hosts regular training sessions in molecular and cellular biology. The project will be developed in Center of Cancer Immunotherapy headed by Dr S. Amigorena and the Clinic Immunology Laboratory headed by Dr O. Lantz. The Immunology Department headed by Dr. AM Lennon includes 8 independent research teams in the fields of basic and applied immunology, working in a very collaborative and international environment. Candidate will work under the supervision of Dr. Olivier Lantz and Dr. F. Lucibello. The aim of the team is to characterize the biology of T cells, their interaction with other cells of the immune system, and their role in cancer, in both humans and through mice models. The open position is in line with recent developments at the interface between Immunology and Cancer (Bigot et al. Cancer Discovery, 2021; Lucibello et al., JEM, 2024). More information: www.curie.fr and http://u932.curie.fr/.

Missions

The research group of Dr. Olivier Lantz (Inserm U932, Paris, France) is seeking a postdoctoral fellow in immunology and oncology. The successful candidate will work on projects focused on the identification and validation of tumor-specific neoantigens shared between patients with non-small cell lung cancer NSCLC.

The project aims to characterize tumor-specific T cell responses directed against neoantigens in human cancer. In silico–predicted neoantigens will be evaluated using immunopeptidomics approaches. Following the identification of the most promising epitopes, their spontaneous immunogenicity and the T cell responses they elicit in patients will be assessed.

Immune responses induced in NSCLC patients treated with immunotherapy will be analyzed in both blood, tumor draining lymphonode and tumor samples. Tumor-specific T cells will be studied using flow cytometry, single-cell technologies (including single-cell RNA sequencing), tetramer staining, and functional assays such as in vitro T cell culture and cytotoxicity (killing) assays. Bioinformatics skills will be considered a strong asset.

The candidate will work in close collaboration with two engineers within the research team and with F. Lucibello.